Epstein Secrets

cessful execution of a business plan or the reduction in risk associated with achieving projected results." The framework of our analysis addresses Hardiman's concerns. The following section describes references to specific studies incorporating comparisons of Company-specific factors (e.g., revenues, ea

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

cessful execution of a business plan or the reduction in risk associated with achieving projected results." The framework of our analysis addresses Hardiman's concerns. The following section describes references to specific studies incorporating comparisons of Company-specific factors (e.g., revenues, ea

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

cessful execution of a business plan or the reduction in risk associated with achieving projected results." The framework of our analysis addresses Hardiman's concerns. The following section describes references to specific studies incorporating comparisons of Company-specific factors (e.g., revenues, ea

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th